Research programme: melanocortin-4 receptor agonists - Eli Lilly

Drug Profile

Research programme: melanocortin-4 receptor agonists - Eli Lilly

Alternative Names: MC4R agonists

Latest Information Update: 22 Apr 2009

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Peptides; Small molecules
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Obesity

Most Recent Events

  • 10 Apr 2007 Data presented at the 233rd American Chemical Society National Meeting (ACS-2007) added to the Obesity pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top